Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications

Journal of Controlled Release

Volumn 266, Issue , 2017, Pages 17-26

  Liu, Chang ^a   Zhang, Li ^a   Liu, Hao ^a   Cheng, Kun ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

CRISPR Cas9; Delivery; Gene therapy; Gene editing; Nanoparticle; Non viral delivery

Indexed keywords

CELL ENGINEERING; NANOPARTICLES; NUCLEIC ACIDS;

ADAPTIVE IMMUNE SYSTEMS; CANCER IMMUNOTHERAPY; CRISPR-CAS9; DELIVERY; DISEASE-CAUSING GENE; MOLECULAR MECHANISM; NON-VIRAL DELIVERIES; THERAPEUTIC APPLICATION;

GENE THERAPY;

CELL PENETRATING PEPTIDE; DNA; GOLD NANOPARTICLE; LIPID; NANOMATERIAL; POLYMER;

ADENO ASSOCIATED VIRUS; CRISPR-CAS9 SYSTEM; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EDITING; HUMAN; HYDRODYNAMICS; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MICROINJECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CRISPR CAS SYSTEM; GENE THERAPY; GENE TRANSFER; VIRUS;

ANIMALS; CRISPR-CAS SYSTEMS; GENE EDITING; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; VIRUSES;

EID: 85029473395     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.09.012     Document Type: Review

References (118)

1. Ishino, Y., Shinagawa, H., Makino, K., Amemura, M., Nakata, A., Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J. Bacteriol. 169 (1987), 5429–5433.
2. Jansen, R., van Embden, J.D.A., Gaastra, W., Schouls, L.M., Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 43 (2002), 1565–1575.
3. Jansen, R., van Embden, J.D., Gaastra, W., Schouls, L.M., Identification of a novel family of sequence repeats among prokaryotes. OMICS 6 (2002), 23–33.
4. Mojica, F.J.M., Diez-Villasenor, C., Garcia-Martinez, J., Soria, E., Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60 (2005), 174–182.
5. Deltcheva, E. et al., CRISPR RNA maturation by trans‑encoded small RNA and host factor RNase III. Nature, 471, 2011, 602.
6. Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337 (2012), 816–821.
7. Cong, L. et al., Multiplex genome engineering using CRISPR/Cas systems. Science 339 (2013), 819–823.
8. Travis, J., Genetic Engineering. Germline editing dominates DNA summit. Science 350 (2015), 1299–1300.
9. Shen, B. et al., Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 23 (2013), 720–723.
10. Veres, A. et al., Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15 (2014), 27–30.
11. Sampson, T.R., Weiss, D.S., Exploiting CRISPR/Cas systems for biotechnology. BioEssays 36 (2014), 34–38.
12. Khatodia, S., Bhatotia, K., Passricha, N., Khurana, S.M., Tuteja, N., The CRISPR/Cas genome-editing tool: application in improvement of crops. Front. Plant Sci., 7, 2016, 506.
13. Yuan, M., Webb, E., Lemoine, N.R., Wang, Y.H., CRISPR-Cas9 as a powerful tool for efficient creation of oncolytic viruses. Viruses, 8, 2016.
14. Schumann, K. et al., Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 10437–10442.
15. Cyranoski, D., CRISPR gene-editing tested in a person for the first time. Nature, 539, 2016, 479.
16. Makarova, K.S. et al., An updated evolutionary classification of CRISPR-Cas systems. Nat. Rev. Microbiol. 13 (2015), 722–736.
17. van der Oost, J., Westra, E.R., Jackson, R.N., Wiedenheft, B., Unravelling the structural and mechanistic basis of CRISPR-Cas systems. Nat. Rev. Microbiol. 12 (2014), 479–492.
18. Garneau, J.E. et al., The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468 (2010), 67–71.
19. Makarova, K.S. et al., Evolution and classification of the CRISPR-Cas systems. Nat. Rev. Microbiol. 9 (2011), 467–477.
20. Gasiunas, G., Sinkunas, T., Siksnys, V., Molecular mechanisms of CRISPR-mediated microbial immunity. Cell. Mol. Life Sci. 71 (2014), 449–465.
21. Doudna, J.A., Charpentier, E., Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science, 346, 2014, 1258096.
22. Hsu, P.D., Lander, E.S., Zhang, F., Development and applications of CRISPR-Cas9 for genome engineering. Cell 157 (2014), 1262–1278.
23. Yosef, I., Goren, M.G., Qimron, U., Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli. Nucleic Acids Res. 40 (2012), 5569–5576.
24. Brouns, S.J. et al., Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321 (2008), 960–964.
25. Westra, E.R., Buckling, A., Fineran, P.C., CRISPR-Cas systems: beyond adaptive immunity. Nat. Rev. Microbiol. 12 (2014), 317–326.
26. Ran, F.A. et al., Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8 (2013), 2281–2308.
27. Niu, Y. et al., Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156 (2014), 836–843.
28. Zuris, J.A. et al., Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33 (2015), 73–80.
29. Fu, Y. et al., High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31 (2013), 822–826.
30. Cradick, T.J., Fine, E.J., Antico, C.J., Bao, G., CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res., 2013 gkt714.
31. Shen, B. et al., Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods 11 (2014), 399–402.
32. Li, L., Natarajan, P., Allen, C., Peshwa, M.V., Cgmp-compliant, clinical scale, non-viral platform for efficient gene editing using Crispr/Cas9. Cytotherapy, 16, 2014 S37-S37.
33. Kim, S., Kim, D., Cho, S.W., Kim, J., Kim, J.S., Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 24 (2014), 1012–1019.
34. Qin, W. et al., Efficient CRISPR/Cas9-mediated genome editing in mice by zygote electroporation of nuclease. Genetics 200 (2015), 423–430.
35. Gori, J.L. et al., Delivery and specificity of CRISPR/Cas9 genome editing technologies for human gene therapy. Hum. Gene Ther. 26 (2015), 443–451.
36. D'Astolfo, D.S. et al., Efficient intracellular delivery of native proteins. Cell 161 (2015), 674–690.
37. Katz, M.G., Fargnoli, A.S., Williams, R.D., Bridges, C.R., Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications. Hum. Gene Ther. 24 (2013), 914–927.
38. Tebas, P. et al., Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370 (2014), 901–910.
39. Mali, P. et al., RNA-guided human genome engineering via Cas9. Science 339 (2013), 823–826.
40. Thummel, R. et al., Inhibition of zebrafish fin regeneration using in vivo electroporation of morpholinos against fgfr1 and msxb. Dev. Biol., 295, 2006 356-356.
41. Nakamura, H., Katahira, T., Sato, T., Watanabe, Y., Funahashi, J., Gain- and loss-of-function in chick embryos by electroporation. Mech. Dev. 121 (2004), 1137–1143.
42. Fei, J.F., Haffner, C., Huttner, W.B., 3′ UTR-dependent, miR-92-mediated restriction of Tis21 expression maintains asymmetric neural stem cell division to ensure proper neocortex size. Cell Rep. 7 (2014), 398–411.
43. Yang, H. et al., One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154 (2013), 1370–1379.
44. Mandal, P.K. et al., Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 15 (2014), 643–652.
45. Hou, Z.G. et al., Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 15644–15649.
46. Ding, Q.R. et al., Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs. Cell Stem Cell 12 (2013), 393–394.
47. Mali, P. et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol., 31, 2013, 833.
48. Fei, J.-F. et al., Tissue-and time-directed electroporation of CAS9 protein–gRNA complexes in vivo yields efficient multigene knockout for studying gene function in regeneration. npj Regen. Med., 1, 2016, 16002.
49. Liang, X.Q. et al., Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208 (2015), 44–53.
50. Chang, N. et al., Genome editing with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 23 (2013), 465–472.
51. Crispo, M. et al., Efficient generation of myostatin knock-out sheep using CRISPR/Cas9 technology and microinjection into zygotes. Plos One, 10, 2015.
52. Mashiko, D. et al., Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci. Rep., 3, 2013.
53. Mashiko, D. et al., Feasibility for a large scale mouse mutagenesis by injecting CRISPR/Cas plasmid into zygotes. Develop. Growth Differ. 56 (2014), 122–129.
54. Yan, Q. et al., Generation of multi-gene knockout rabbits using the Cas9/gRNA system. Cell Regen., 3, 2014, 12.
55. Hruscha, A., Schmid, B., Generation of Zebrafish models by CRISPR/Cas9 genome editing. Neuronal Cell Death 1254 (2015), 341–350.
56. Sasaki, H., Yoshida, K., Hozumi, A., Sasakura, Y., CRISPR/Cas9-mediated gene knockout in the ascidian Ciona intestinalis. Develop. Growth Differ. 56 (2014), 499–510.
57. Friedland, A.E. et al., Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat. Methods, 10, 2013, 741.
58. Basu, S. et al., Silencing of end-joining repair for efficient site-specific gene insertion after TALEN/CRISPR mutagenesis in Aedes aegypti. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 4038–4043.
59. Nakagawa, Y. et al., Production of knockout mice by DNA microinjection of various CRISPR/Cas9 vectors into freeze-thawed fertilized oocytes. Bmc Biotechnol., 15, 2015.
60. Horii, T. et al., Validation of microinjection methods for generating knockout mice by CRISPR/Cas-mediated genome engineering. Sci. Rep., 4, 2014.
61. Ramakrishna, S. et al., Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA. Genome Res. 24 (2014), 1020–1027.
62. Suresh, B., Ramakrishna, S., Kim, H., Cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA for genome editing. Methods Mol. Biol. 1507 (2017), 81–94.
63. Worthen, C., Rittié, L., Fisher, G., Mechanical deformation of cultured cells with hydrogels. Methods Mol. Biol. 1627 (2017), 245–251.
64. Sharei, A. et al., A vector-free microfluidic platform for intracellular delivery. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 2082–2087.
65. Han, X. et al., CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation. Sci. Adv., 1, 2015, e1500454.
66. Al-Dosari, M.S., Knapp, J.E., Liu, D., Hydrodynamic delivery. Adv. Genet. 54 (2005), 65–82.
67. Liu, F., Song, Y., Liu, D., Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6 (1999), 1258–1266.
68. Suda, T., Liu, D., Hydrodynamic delivery. Adv. Genet. 89 (2015), 89–111.
69. Suda, T., Liu, D., Hydrodynamic gene delivery: its principles and applications. Mol. Ther. 15 (2007), 2063–2069.
70. Zhen, S. et al., Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther. 22 (2015), 404–412.
71. Xue, W. et al., CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514 (2014), 380–384.
72. Yin, H. et al., Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32 (2014), 551–553.
73. Khorsandi, S.E. et al., Minimally invasive and selective hydrodynamic gene therapy of liver segments in the pig and human. Cancer Gene Ther. 15 (2008), 225–230.
74. Fitzgerald, K. et al., Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383 (2014), 60–68.
75. Coelho, T. et al., Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369 (2013), 819–829.
76. Raghavan, A. et al., High-throughput screening and CRISPR-Cas9 modeling of causal lipid-associated expression quantitative trait locus variants. bioRxiv, 2016, 056820.
77. Platt, R.J. et al., CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159 (2014), 440–455.
78. Wang, M. et al., Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), 2868–2873.
79. Kang, Y.K. et al., Nonviral genome editing based on a polymer-derivatized CRISPR nanocomplex for targeting bacterial pathogens and antibiotic resistance. Bioconjug. Chem. 28 (2017), 957–967.
80. Hu, R. et al., DNA nanoflowers for multiplexed cellular imaging and traceable targeted drug delivery. Angew. Chem. Int. Ed. Eng. 53 (2014), 5821–5826.
81. Sun, W.J. et al., Self-assembled DNA Nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. 54 (2015), 12029–12033.
82. Mout, R. et al., Direct cytosolic delivery of CRISPR/Cas9-ribonucleoprotein for efficient gene editing. ACS Nano, 2017.
83. Maggio, I. et al., Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. Sci. Rep., 4, 2014.
84. Yusa, K., Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Hum. Gene Ther., 26, 2015 A3-A3.
85. Koike-Yusa, H., Li, Y.L., Tan, E.P., Velasco-Herrera, M.D., Yusa, K., Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat. Biotechnol. 32 (2014), 267–273.
86. Shalem, O. et al., Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 (2014), 84–87.
87. Paulk, N.K. et al., Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51 (2010), 1200–1208.
88. Gaj, T., Epstein, B.E., Schaffer, D.V., Genome engineering using adeno-associated virus: basic and clinical research applications. Mol. Ther. 24 (2016), 458–464.
89. Sonntag, F., Schmidt, K., Kleinschmidt, J.A., A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 10220–10225.
90. Grimm, D. et al., In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82 (2008), 5887–5911.
91. Grimm, D., Kay, M.A., From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3 (2003), 281–304.
92. Yla-Herttuala, S., Endgame: glybera finally recommended for approval as the first gene therapy drug in the European Union. Mol. Ther. 20 (2012), 1831–1832.
93. Wu, Z.J., Yang, H.Y., Colosi, P., Effect of genome size on AAV vector packaging. Mol. Ther. 18 (2010), 80–86.
94. Ran, F.A. et al., In vivo genome editing using Staphylococcus aureus Cas9. Nature 520 (2015), 186–U198.
95. Friedland, A.E. et al., Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome Biol., 16, 2015.
96. Swiech, L. et al., In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nat. Biotechnol. 33 (2015), 102–U286.
97. Yang, Y. et al., A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat. Biotechnol., 34, 2016, 334.
98. Zetsche, B., Volz, S.E., Zhang, F., A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 33 (2015), 139–142.
99. Zufferey, R. et al., Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72 (1998), 9873–9880.
100. Schnell, T., Foley, P., Wirth, M., Munch, J., Uberla, K., Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum. Gene Ther. 11 (2000), 439–447.
101. Aiuti, A. et al., Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341 (2013), 865–U871.
102. Cartier, N. et al., Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 (2009), 818–823.
103. Wang, T., Wei, J.J., Sabatini, D.M., Lander, E.S., Genetic screens in human cells using the CRISPR-Cas9 system. Science 343 (2014), 80–84.
104. Kabadi, A.M., Ousterout, D.G., Hilton, I.B., Gersbach, C.A., Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Nucleic Acids Res., 42, 2014, e147.
105. Wang, X. et al., Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33 (2015), 175–178.
106. Kabadi, A.M., Ousterout, D.G., Hilton, I.B., Gersbach, C.A., Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector. Mol. Ther., 22, 2014 S124-S124.
107. Zhou, Y. et al., High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells. Nature 509 (2014), 487–491.
108. Chen, S.D. et al., Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160 (2015), 1246–1260.
109. Heck, D. et al., Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat. Biotechnol. 32 (2014), 941–946.
110. Blasco, R.B. et al., Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Rep. 9 (2014), 1219–1227.
111. Wang, J.B., Quake, S.R., RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 13157–13162.
112. Kaminski, R. et al., Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. vol 6, 22555, 2016 Sci Rep, 6, 2016.
113. Dong, C.S. et al., Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antivir. Res. 118 (2015), 110–117.
114. Seeger, C., Sohn, J.A., Targeting Hepatitis B Virus With CRISPR/Cas9. Mol. Ther., 3, 2014.
115. Ramanan, V. et al., CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci. Rep., 5, 2015.
116. Mulvihill, J.J. et al., Ethical issues of CRISPR technology and gene editing through the lens of solidarity. Br. Med. Bull. 122 (2017), 17–29.
117. Mout, R., Ray, M., Lee, Y.W., Scaletti, F., Rotello, V.M., In vivo delivery of CRISPR/Cas9 for therapeutic gene editing: progress and challenges. Bioconjug. Chem. 28 (2017), 880–884.
118. Yin, H. et al., Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34 (2016), 328–333.